Eagle Capital Growth Fund Inc (GRF) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form N-PX - Annual Report of proxy voting record of management investment companies

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339

GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic...

Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients

XEMBIFY is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for...

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in...

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

With today’s announcement of the transaction completion, Grifols and Haier Group will work together through...

Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies

With Biotest-developed Yimmugo, Grifols adds to its remarkable franchise of intravenous and subcutaneous...

Form 4 - Statement of changes in beneficial ownership of securities

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a...

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of...

Form DEF 14A - Other definitive proxy statements

Form N-CSR - Certified Shareholder Report

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)